Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Hematology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1440712
This article is part of the Research Topic Differential Diagnosis of Erythrocytosis and Analysis of Their Clinical Utility View all 3 articles

Utility of Next-Generation Sequencing in Identifying Congenital Erythrocytosis in Patients with Idiopathic Erythrocytosis

Provisionally accepted
Saša Anžej Doma Saša Anžej Doma 1,2*Nika Kraljić Nika Kraljić 1Aleša Kristan Aleša Kristan 3Nataša Debeljak Nataša Debeljak 3Aleš Maver Aleš Maver 4Tadej Pajič Tadej Pajič 4Irena Preložnik Zupan Irena Preložnik Zupan 1,2
  • 1 Department of Hematology, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • 2 Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  • 3 Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  • 4 Clinical Institute of Genomic Medicine, University Medical Centre Ljubljana, Ljubljana, Slovenia

The final, formatted version of the article will be published soon.

    Background: Congenital erythrocytosis (CE) is increasingly recognized as the cause of erythrocytosis in patients in whom polycythemia vera and secondary acquired causes have been excluded. The aim of our study was to determine possible genetic background in patients with idiopathic erythrocytosis. Methods: 40 patients with idiopathic erythrocytosis, referred to our institution in a 5-year period, were analyzed. We collected data on erythropoietin (Epo) levels, hemoglobin (Hgb), hematocrit (Hct), erythrocyte count, age, gender, past thrombotic events, concomitant diseases, and smoking status. CE was tested using next-generation sequencing (NGS), in the majority of patients also measurement of P50 and Hgb electrophoresis were performed. Patients with signs of iron overload were tested for genetic variants in the HFE gene. Results: The median patient age at analysis was 46.5 years (range 22-73), with 37 out of 40 being males (93 %). The median Hgb, Hct and red blood cells count were 180 g/L, 0.51, 5.985 x 1012/L in men and 171 g/L, 0.50 and 5.68 x 1012/L in women, respectively. Epo levels were decreased in three, increased in one patient and within the normal range in the rest (median 7.55 mIU/mL; range 2.90-19.50). Eight patients (20 %) smoked. 32 (80 %) were treated with low-dose aspirin, and 20 (50 %) underwent at least one phlebotomy. Thromboembolic events were recorded in 2 patients (5 %). P50 was measured in 20 out of 40 patients, and it was above 24 mm Hg (3.12 kPa) in all of them. Hemoglobin electrophoresis was performed in 73 % of patients, with no abnormal Hgb detected. Variants in the HFE gene were found in 8 out of 40 patients (20 %), but in only one patient the results were associated with an increased risk for hemochromatosis. Although no pathogenic variants for CE were detected by NGS, two variants of uncertain significance, namely EGLN1 (NM_022051.2):c.1072C>T (p.(Pro358Ser)) and EGLN1 (NM_022051.2):c.1124A>G (p.(Glu375Gly)) were identified as strong etiologic candidates. Conclusion: CE is an extremely rare condition. Genetic testing is advised in young individuals with a long-standing persistent erythrocytosis, possibly with a family history and after exclusion of more frequent secondary causes and polycytemia vera.

    Keywords: Non-clonal, Erythrocytosis, Congenital erythrocytosis, Next-generation sequencing, Erythropoietin, Hemochromatosis

    Received: 29 May 2024; Accepted: 19 Aug 2024.

    Copyright: © 2024 Anžej Doma, Kraljić, Kristan, Debeljak, Maver, Pajič and Preložnik Zupan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Saša Anžej Doma, Department of Hematology, University Medical Centre Ljubljana, Ljubljana, Slovenia

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.